Radiotherapeutic management of locally advanced head and neck cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 3, 2006, Pages 405-417

  Ghosh Laskar, Sarbani ^a   Agarwal, J P ^a   Srinivas, C ^a   Dinshaw, K A ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Head and neck cancer; Locally advanced; Radiotherapy

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; AMIFOSTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETANIDAZOLE; FLUOROURACIL; GEFITINIB; GEMCITABINE; METRONIDAZOLE; MISONIDAZOLE; MITOMYCIN; NIMORAZOLE; OXYGEN; PIMONIDAZOLE; PLACEBO; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE; TIRAPAZAMINE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG TARGETING; DYSPHAGIA; ECHOGRAPHY; EVIDENCE BASED MEDICINE; EXPERIENCE; EYE DISEASE; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HEALTH CARE DELIVERY; HIGH RISK PATIENT; HUMAN; HYPERBARIC OXYGEN; HYPOPHARYNX CANCER; IMAGE ANALYSIS; INTENSITY MODULATED RADIATION THERAPY; JAW DISEASE; LARYNX CANCER; LARYNX DISORDER; LYMPH NODE METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAROTID GLAND DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREDICTION; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOBIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; SPINAL CORD DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; XEROSTOMIA; ADJUVANT THERAPY; HEAD AND NECK TUMOR; KINETICS; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; KINETICS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SIGNAL TRANSDUCTION; SURVIVAL;

EID: 33644920388     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.3.405     Document Type: Review

References (63)

1. Dinshaw KA, Rao DN, Ganesh B. Hospital Cancer Registry: Annual report 2000. Tata Memorial Hospital (TMH). 6 (2003).
2. Fletcher GH. Scientific basis of present and future practice of clinical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 9, 1073-1082 (1983).
3. Mendenhall WM, Parsons JT, Cassisi NJ et al. Squamous cell carcinoma of tonsillar area treated with radical irradiation. Radiother. Oncol. 10, 23-30 (1987).
4. Lee WR, Mendenhall WM, Parsons JT et al. Carcinoma of the tonsillar region: a multivariate analysis of 243 patients treated with radical radiotherapy. Head Neck 15, 283-288 (1993).
5. Fletcher GH, Evers WT. Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck. Radiology 95(1), 185-188 (1970).
6. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. Clin. Otolaryngol. 7(3), 185-192 (1982).
7. Vikram B, Strong EW, Shaw JP, Spiro R. Failure at the primary site following multimodality treatment in advanced head and neck cancer. Head Neck Surg. 6(3), 720-723 (1984).
8. Kramer S, Gelber RD, Snow GB et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiaition Therapy Oncology Group. Head Neck Surg. 10(1), 19-30 (1987).
9. Peters LJ, Goepfert H, Ang KK et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomised trial. Int. J. Radiat. Oncol. Biol. Phys. 26(1), 3-11 (1993).
10. Dinshaw KA, Agarwal JP, Laskar SG, Gupta T, Shrivastava SK, D'Cruz AK. Head and neck squamous cell carcinoma: the role of post operative adjuvant radiotherapy. J. Surg. Oncol. 91, 48-55 (2005).
11. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Dalyschveitzer N. Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 36(5), 999-1004 (1996).
12. Cooper JS, Pajak TF, Forastiere A et al. Postoperative concurrent radiotherapy and chemotherapy for high risk squamous cell carcinoma of the head and neck. N. Engl. J. Med. 350(19), 1937-1944 (2004).
13. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer N. Engl. J. Med. 350(19), 1945-1952, (2004).
14. Laramore GE, Scott CB, al-Sarraf M et al. Adjuvant chemotherapy for respectable squamous cell carcinoma of the head and neck: report on Intergroup study 0034. Int. J. Radiat. Oncol. Biol. Phys. 23(4), 705-713 (1992).
15. VA Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancers. N. Engl. J. Med. 324 (24), 1685-1690 (1991).
16. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette C, Sahmoud T. Larynx preservation in pyriform sinus: preliminary results of a European Organization for Research and Treatment of Cancer Phase III Trial. EORTC Head and Neck Cancer Cooperative group. J. Natl Cancer Inst. 88(13), 890-899 (1996).
17. Lefebvre JL, Chevalier D, Luboinski B et al. Is laryngeal preservation with induction chemotherapy safe in the treatment of hypopharyngeal SCC? Final results of Phase III EORTC trial 24891 trial. J. Clin. Oncol. 2004 ASCO Annual Meeting proceedings. 22148 (Suppl. 5531) (2004).
18. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Eng. J. Med. 349(22), 2091-2098 (2003).
19. Soo KC, Tan EH, Wee J et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in Stage III/IV non-metastatic squamous cell head and neck cancer - a randomized comparision. Br. J. Cancer 93, 279-285 (2005).
20. Kies MS, Haraf DJ, Roser F et al. Concomitant infusional paclitaxel and flourouracil, oral hydroxyurea and hyperfractionated radiation for locally advanced squamous head and neck cancer. J. Clin. Oncol. 19(7), 1961-1969 (2001).
21. Adelstein DJ, Li Y, Adams GL et al. An Intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21(1), 92-98 (2003).
22. Vokes EE, Stenson K, Roseb FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, flourouracil and hydroxyurea chemoradiotherapy: curative and organ preserving therapy for advanced head and neck cancer. J. Clin. Oncol. 21(2), 320-326 (2003).
23. Stell PM, Rawson NSB. Adjuvant chemotherapy in head and neck cancer. Br. J. Cancer 61, 779-787 (1990).
24. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br. J. Cancer 71, 83-91 (1995).
25. El Sayed, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of head and neck region. A meta-analysis if prospective and randomized trials. J. Clin. Oncol. 14(3), 838-847 (1996).
26. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: 3 meta- analysis of updated individual data. MACH-NC collaborative Group Meta-analysis of chemotherapy on Head and Neck Cancer. Lancet 355 (9208), 949-955 (2000).
27. Bourhis J, Amand C, Pignon JP. Update of MACH-NC (Mesa-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J. Clin. Oncol. 2004 ASCO Annual Meeting Proceedings. 22, 14S (Suppl. 5505) (2004).
28. Milano MT, Haraf DJ, Stenson KM et al. Phase I study concomitant chemoradiotherapy with paclitaxel, flourouracil, gemcitabine, and twice-daily radiation in patients with poor prognosis cancer of the head and neck. Clin. Cancer Res. 10(15), 4922-4932 (2004).
29. Correa PD, Arya S, Lascar SG et al. Ultrasonographic changes in malignant neck nodes during radiotherapy in head and neck squamous carcinoma. Austalas. Radiol. 49, 113-118 (2005).
30. Eisbruch A, Ship JA, Mortel MK et al. Parotid glands sparing in patients undergoing bilateral head and neck irradiation. Techniques and early results. Int. J. Radiat. Oncol. Biol. Phys. 36, 469-480 (1996).
31. Eisbruch A, Marsh LH, Mortel MK et al. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and non-involved tissue sparing. Int. J. Radiat. Oncol. Biol. Phys. 41, 559-568 (1998).
32. Eisbruch A, Ten Haken RK, Kim HM et al. Dose volume and function relationships in parotid salivary glands following conformal and intensity modulated irradiation of head and neck cancer. Int. J. Radiat. Oncol. Biol. Pphys. 45, 577-587 (1999).
33. Chao KSC, Deasy JD, Markman J et al. A prospective study of salivary function sparing in patients with head and neck cancers receiving intensity modulated or 3-dimensional radiation therapy. Initial results. Int. J. Radiat. Oncol. Biol. Phys. 49, 907-916 (2005).
34. Lee N, Xia P, Quisey J et al. Intensity modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of UCSF experience. Int. J. Radiat. Oncol. Biol. Phys. 53, 12-22 (2002).
35. Chao KSC, Ozygit G, Tran BN et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 55, 312-321 (2003).
36. Yau J, Lieskovsky Y, Horst K et al. An evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 57, S156 (2003).
37. Dawson LA, Anzai Y, Marsh L et al. Patterns of local regional recurrence following parotid sparing conformal and segmental intensity modulated radiotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 46, 1117-1126 (2000).
38. Qiuwen WU, Matthew M, Rupert Schmidt-Uhlrich, Radhemohan. The potential for sparing of parotids and escalation of biologically effective dose with intensity modulated radiation treatment of head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 46, 195-205 (2000).
39. Marcial V, Pajak T, Chang C et al. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int. J. Radiat. Oncol. Biol. Phys. 13, 41-47 (1987).
40. Cox JD, Pajak TF, Marcial VA et al. Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group Protocol 8313. Int. J. Radiat. Oncol. Biol. Phys. 20, 1191-1195 (1991).
41. Overgaard J, Hansen HS, Grau C et al. The DAHANCA 6 and 7 trial: a randomised multicentre study of 5 vs 6 fractions per week of conventional radiotherapy of squamous cell carcinoma of the head and neck. Radiother. Oncol. 56(Suppl.), S4 (2000).
42. Jackson SM, Weir LM, Hay JH et al. Randomised trial of accelerated vs. conventional radiotherapy in head and neck cancer. Radiother. Oncol. 43, 39-46 (1996).
43. Skladowski K, Maciejewski J, Golen M et al. Randomised clinical trial on 7-day continuous accelerated irradiation of head and neck cancer: report on 3 year tumor control and normal tissue toxicity. Radiother. Oncol. 55, 93-102 (2000).
44. Hliniak A, Gwiazdowska B, Szutkowski Z et al. Radiotherapy of the laryngeal cancer: the estimation of the therapeutic gain and the enhancement of toxicity by the one week shortening of the treatment time - results of the randomised Phase III multicentre trial. Radiother. Oncol. 56(Suppl.) S5 (2000).
45. Fu KK, Pajak TF, Trotti A et al. A radiation therapy oncology group Phase III randomised study to compare Hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: 1st report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 48, 7-16 (2000).
46. Pinto L, Canary P, Araujo C et al. Prospective randomised trial comparing fractionated vs. conventional radiotherapy in Stages III & IV oropharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 21, 557-562 (1991).
47. Cummings B, O'Sullivan B, Keane T et al. 5 year results of a 4 week/ twice daily radiation schedule. Radiother. Oncol. 56(Suppl.) S8 (2000).
48. Dische S, Saunders M, Barrett A et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 44, 123-136 (1997).
49. Poulsen MG, Denham JW, Peters LJ et al. A randomised trial of accelerated and conventional radiotherapy for Stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother. Oncol. 60, 113-122 (2001).
50. Fu KK, Pajak TF, Trotti A et al. A radiation therapy oncology group (RTOG) Phase III randomized study to compare hyperfractionationand two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: fast report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 48, 7-16 (2000).
51. Dobrowsky W, Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother. Oncol. 57, 119-124 (2000).
52. Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized german trial in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 50, 1161-1171 (2001).
53. Bourhis J, Lapeyre M, Tortochaux J et al. Preliminary results of the GORTEC 96-01 randomized trial, comparing very accelerated radiotherapy versus concomitant radio-chemotherapy for locally inoperable HNSCC. Int. J. Radiat. Oncol. Biol. Phys. 51 (Suppl. 1), 39 (2001).
54. Jeremic B, Shibamoto Y, Milicic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J. Clin. Oncol. 18, 1458-1464 (2000).
55. Olmi P, Crispino S, Fallai C, Valter T, F Rossi, A Bolner et al. Locoregionally advanced carcinoma of the oropharynx: Conventional radiotherapy vs accelerated hyperfractionated vs concomitant radiotherapy and chemotherapy - a multicenter randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 55, 78-82 (2003).
56. Chris HJT, Henk BK, Gerrit JH et al. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in Week 3. Int. J. Radiat. Oncol. Biol. Phys. 62, 62-69 (2005).
57. Bonner JA, Giralt J, Harari PM et al. Cetuximab prolongs survival in patients with locoregionally advanced Squamous cell carcinoma of head and neck: a Phase III study of high dose radiation therapy with or without cetuximab. J. Clin. Oncol. ASCO Proceedings 2214S (July 15 (Suppl.) 5507 (2004).
58. Overgaard J, Sand Hansen H, Lindelov B et al. Nimorazole as a hypoxic sensitizer in the treatment of supraglottic larynx and pharynx carcinoma: first report from the Danish Head and Neck Cancer study protocol. Radiother. Oncol. 20(Suppl. 1), 143-150 (1991).
59. Overgaard J, Sand Hansen H, Andersen AP et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx. Final report from DAHANCA 2 study. Int. J. Radiat. Oncol. Biol. Phys. 16, 1065-1068 (1989).
60. Overgaard J, Horsman MR. Modification of hypoxixia induced radioresistance in tumors by the use of oxygen and sensitizers. Semin. Radiat. Oncol. 6, 10-21 (1996).
61. Cai Grau, JP Agarwal, Kaukab J et al. Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the multicentre randomised IAEA trial. Radiother. Oncol. 67, 17-26 (2003).
62. Brizel DM, Wasserman TH, Henke M et al. Phase III randomised trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18, 3339-3345 (2000).
63. Andre DS, De Oliveira Clark LG, Emma CS, Clark OA. Amifostine reduces side-effects and improves complete response rate during radiotherapy: results of a met-analysis. Int. J. Radiat. Oncol. Biol. Phys. 64, 784-791 (2005).